title: Interpretation of idarucizumab clinical trial data based on spontaneous reports of dabigatran adverse effects in the French pharmacovigilance database.
authors: St Esprit Hospital, Emergency Department, Agen, France.
authors: Albert
authors: A
authors: Trinh-Duc
authors: AP-HP, European Hospital Georges Pompidou, Pharmacovigilance Department, Paris, France.
authors: Agnès
authors: A
authors: Lillo-Le Louët
authors: St Esprit Hospital, Emergency Department, Agen, France.
authors: Eric
authors: E
authors: Tellier
authors: St Esprit Hospital, Emergency Department, Agen, France.
authors: Thibault
authors: T
authors: Viard
authors: Université de Brest, EA3878 Brest, France; University of Ottawa, Department of Medicine, Ottawa, Canada.
authors: Grégoire
authors: G
authors: Le Gal
authors: Paris Descartes University, Sorbonne Paris Cité, Paris, France; Inserm UMR-S1140, Paris, France; AP-HP, European Hospital Georges Pompidou, Hematology Department, Paris, France. Electronic address: david.smadja@aphp.fr.
authors: David M
authors: DM
authors: Smadja
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000069604:Dabigatran / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005602:France; D006801:Humans; D060735:Pharmacovigilance
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C000594745:idarucizumab; D000069604:Dabigatran